Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698136 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL14255648 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL13698137 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL8209415 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL4185668 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL4912928 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL18327296 | 0.85 | SLC6A4 (0.45) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL8220956 | 0.85 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL8214880 | 0.85 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL8216627 | 0.85 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008013856-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL -3-AZABICYCLO[3.1.0 ] HEXANES | DOV PHARMACEUTICAL, INC. (US) | 2008-01-31 | — | — | WO | disclosed |